Indivior Looks To Cement Addiction Drug Leadership With Opiant Buy
Paying $145m Upfront Plus CVR
Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.
